Preclinical company Azitra has raised a small bag of cash in its Series A round as it looks to further its work using the skin’s own microbiome for new treatments in dermatology and skin infections.

The three-year-old Farmington, Connecticut-based biotech recentl closed a $2.9 million venture round led by Bios Partners, which brings its total amount of outside funding to $3.75 million.